naratriptan tablets launched in the us

1
Narahiptan tablets launched in the US MARKET NEWS The tablet formulation of naratriptan ['Amerge'; Glaxo Wellcome] has been launched in the US for the acute treatment of migraine. Naratriptan, a 5-HT 1BIID agonist, has already been approved in 14 countries and will now be available in tho. "u,' 1 .., 4\",,0' t-::.hl,:.t" •• '"' ...... - t.4J ... -o"'.&&&b .., ..... "" •• 0 .... "'-..,._ .. ..,. According to Glaxo Wellcome, naratriptan therapy is associated with a low rate of headache recurrence (between 19 and 28% within 24 hours), reports Marketletter. 'Amerge' is indicated for patients with migraine who have long-lasting or recurrent headaches or who are unable to tolerate other anti-migraine products. Naratriptan launched in the USA. Marketletter 25: 21, 30 Mar 1998 _ 1173-832419811132-000211$01.00° Adialnternlltionel Limited 1998. All righta.--wel 21 Inphanna-11 Apr 1998 No. 1132

Post on 12-Dec-2016

217 views

Category:

Documents


2 download

TRANSCRIPT

Page 1: Naratriptan tablets launched in the US

Narahiptan tablets launched in the US

MARKET NEWS

The tablet formulation of naratriptan ['Amerge'; Glaxo Wellcome] has been launched in the US for the acute treatment of migraine.

Naratriptan, a 5-HT1BIID agonist, has already been approved in 14 countries and will now be available in tho. TT~ "u,' 1 I()"~ .., 4\",,0' "'tr~nnth t-::.hl,:.t" ~ •• '"' ...... - t.4J ... -....~ -o"'.&&&b .., ..... "" •• 0 .... "'-..,._ .. ..,.

According to Glaxo Wellcome, naratriptan therapy is associated with a low rate of headache recurrence (between 19 and 28% within 24 hours), reports Marketletter.

'Amerge' is indicated for patients with migraine who have long-lasting or recurrent headaches or who are unable to tolerate other anti-migraine products.

Naratriptan launched in the USA. Marketletter 25: 21, 30 Mar 1998 _

1173-832419811132-000211$01.00° Adialnternlltionel Limited 1998. All righta.--wel

21

Inphanna-11 Apr 1998 No. 1132